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ABSTRACT. Uncompetitive antagonists of the N-methyl D-aspartate receptor (NMDAR) have 
demonstrated therapeutic benefit in the treatment of neurological diseases such as Parkinson’s and 
Alzheimer’s, but some also cause dissociative effects that have led to the synthesis of illicit drugs. 
The ability to generate NMDAR antagonists in silico is therefore desirable both for new 
medication development and for preempting and identifying new designer drugs. Recently, 
generative deep learning models have been applied to de novo drug design as a means to expand 
the amount of chemical space that can be explored for potential drug-like compounds. In this study, 
we assess the application of a generative model to the NMDAR to achieve two primary objectives: 
(i) the creation and release of a comprehensive library of experimentally validated NMDAR 
phencyclidine (PCP) site antagonists to assist the drug discovery community and (ii) an analysis 
of both the advantages conferred by applying such generative artificial intelligence models to drug 
design and the current limitations of the approach. We apply, and provide source code for, a variety 
of ligand- and structure-based assessment techniques used in standard drug discovery analyses to 
the deep learning-generated compounds. We present twelve candidate antagonists that are not 
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available in existing chemical databases to provide an example of what this type of workflow can 
achieve, though synthesis and experimental validation of these compounds is still required. 
INTRODUCTION. Deep learning (DL)-based technology has been widely adopted in realms such 
as natural language processing and computer vision. The success of DL frameworks in those arenas 
led to their more recent adaption to the cheminformatics field, where they have been employed as 
tools to further elucidate topics ranging from chemical property prediction to synthesis planning.1-
2 Furthermore, DL is playing an increasingly important role in the de novo design of molecules 
with desired chemical properties. It is estimated that there are up to 1060 synthesizable drug-like 
organic compounds in chemical space, over 99.9% of which are theoretically accessible but have 
never been synthesized.3-4 The in silico design and property prediction of biologically active 
compounds is desirable both as a means to explore previously inaccessible areas of chemical space 
and as a labor-, cost-, and time-effective alternative to the in vitro assessment of lead-like 
compounds via high throughput screening. As such, there has been a sizable improvement to in 
silico methodologies for novel molecule generation, discovery, and property prediction in the past 
decade. These computer-assisted drug discovery (CADD) methods also have the potential to 
achieve much higher hit-finding rates than laboratory-based high-throughput screening.5 While the 
application of machine learning to the CADD pipeline in the areas of target, property, and activity 
prediction is widespread,6-7 its application to de novo molecular generation is a more recent 
development—one that, while not currently without notable limitations, is demonstrating great 
potential. 
One standard in silico approach to de novo molecular design is to build a molecule piecewise or 
atom-wise inside a pocket that represents the target protein.8 However, this method can result in 
molecules that are difficult to synthesize, overfit to their target, or both. Another approach is to 
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use virtual chemical reactions to build novel molecules. While this method addresses the 
synthesizability problem, it limits the scope of chemical space that can be explored.1, 9 To avoid 
these pitfalls, inverse quantitative structure-activity relationships (inverse-QSAR) has been 
proposed as an alternate approach to de novo molecular design. The methodology employed by 
inverse-QSAR is to generate compounds by sampling the region of chemical space defined by the 
properties of molecules with known activity.10-12 To this end, DL can be utilized both for learning 
the property space encompassed by the active compounds and for generating novel molecules from 
this space.9, 13-21 A promising recent development involves the application of variational 
autoencoders (VAEs)22 to de novo molecular design.14, 23-25 VAEs are generative DL models 
comprised of two connected networks—an encoder and a decoder. The encoder converts input 
data to a compact representation, shaping the network’s continuous – or latent – space as it learns 
patterns in the input. The decoder samples from the latent space to generate the output. In the case 
of de novo design, the VAE’s latent space represents a chemical space within which known 
molecules can be placed and from which novel molecular structures can be derived. VAE 
architecture is particularly compelling for inverse-QSAR due to its ability to accommodate two-
way traversal: chemical property prediction given input molecular structure or structure generation 
from desired properties.  
Recently, our group developed the VAE-based software DarkChem for mapping chemical 
properties to molecular structure.26 It was originally intended as a tool for in silico metabolomics 
to aid in the identification of small molecules in complex samples. DarkChem’s latent space is 
shaped using calculable chemical properties, such as molecular mass and collision cross section (a 
gas phase property measured by ion mobility spectrometry), to enable rapid construction of 
massive molecular libraries with reduced reliance on experimentation. DarkChem also shows 
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promise in de novo drug design. When a small set of known channel blockers of the NMDAR (N-
methyl D-aspartate receptor) were used as input to DarkChem to generate putative novel 
compounds, principal component analysis (PCA) revealed that the DarkChem-generated 
molecules clustered well according to mass and CCS and warranted a more thorough investigation 
of their capacity as potential NMDAR channel blockers. In an effort to further elucidate both the 
advantages and shortcomings of nascent artificial intelligence-assisted generative approaches like 
DarkChem, we chose to enter the field of computational drug design by exploring how our 
computer-generated molecules perform when applied to filtering and assessment methods 
commonly used during virtual screening of existing large molecular databases. It should be noted 
that while synthesizability was assessed during the course of this study, none of the computer-
generated molecules have been synthesized, as this is outside the scope of our work. Our findings 
are intended to offer guidance both to the development of future versions of DarkChem and to the 
drug design community. We opted to conduct our exploration on a target that has received renewed 
interest for drug leads of late,27-29 yet is lacking in readily available and accessible information 
necessary for many CADD techniques: the NMDAR phencyclidine (PCP) site. As such, a 
secondary goal of this study was to provide a comprehensive PCP site library freely to the research 
community. Furthermore, we evaluated our generative artificial intelligence (AI) model against a 
more challenging target – an active site located in the ion channel of a complex plasma membrane 
protein only recently resolved by X-ray crystallography30 – than those used in literature to date, 
which are largely kinases.16, 18, 25, 31-32 
The NMDAR PCP Site 
The NMDAR is a heterotetrameric, ligand- and voltage-gated glutamate receptor expressed in 
the central nervous system (CNS). Irregular NMDAR function is implicated in excitotoxicity and 
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a host of nervous system disorders including Alzheimer’s, Parkinson’s, and Huntington’s diseases. 
A connection between NMDAR dysfunction and depression has also been proposed, but 
experiments aimed at elucidating the mode of action have yielded ambiguous results.33-34 While 
there are multiple binding sites on the NMDAR (Figure 1), open channel blockers that target the 
PCP site in the ion channel of the transmembrane domain (TMD) have received renewed interest 
due to the recent clinical trial successes of ketamine (a PCP site uncompetitive antagonist) in 
treating major depressive disorder.27-29 Memantine is a PCP site antagonist that is well-tolerated 
and effective in the treatment of Parkinson’s and moderate to severe Alzheimer’s disease.35 Many 
other PCP site antagonists, including the site’s namesake drug PCP and the extremely high-affinity 
channel blocker MK-801 (dizocilpine), result in undesirable dissociative effects in humans that 
negate the potential therapeutic benefit they might confer. Further, many PCP analogs have been 
identified in confiscated street drugs and in the post-mortem setting.36 Due to the nature of known 
PCP site antagonists, the potential benefit of generating novel analogous structures is twofold: to 
aid in the discovery of medicinal drug leads for the treatment of neurological disorders and to 
preempt new designer drugs before they hit the market.  
 
Figure 1. The NMDAR and some of its notable features. (A) The crystal structure of the NMDAR 
derived from Protein Data Bank accession no. 5UOW (Lu et al., 2017) with the amino-terminal 
domain (ATD), ligand-binding domain (LBD), and transmembrane domain (TMD) regions 
BA
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labeled. NR1 and NR2B subunits are isolated for clarity. The high-affinity channel blocker MK-
801 is shown bound in the PCP site in the inset. (B) Cation flow and selected binding sites 
including the glycine and glutamate agonist binding sites are depicted in the schematic. 
 
Despite the significant value the NMDAR has as a target, DL-enabled de novo drug design has 
not been applied to the NMDAR to date – in part due to the lack of publicly available ligand-
protein binding data. To address this data scarcity, we have built a comprehensive NMDAR PCP 
site antagonist library (see Supporting Information). Another impediment to CADD application to 
the NMDAR – and particularly to the PCP site – has been the difficulty in resolving the protein in 
its active state via X-ray crystallography due to its complex structure.37 In 2018, however, Song et 
al. succeeded in resolving a PCP site-bound crystal structure of the NMDAR with a correctly 
assembled TMD channel,30 an achievement noted in part for providing a good assessment tool for 
the binding of NMDAR channel blockers.37 We therefore elected to include a docking study of 
PCP site antagonists using this structure as a component of our assessment. 
 Given the high failure rate of NMDAR antagonists in clinical trials and the frequency with 
which new street drugs that target the PCP site are developed, a primary goal of the molecular 
generation aspect of this study was to produce compounds that are structurally unique compared 
to known PCP site antagonists yet still retain predicted target activity. The discovery of new 
molecular scaffolds and chemical classes with PCP site activity has the potential to aid the 
development of therapeutics without undesirable dissociative effects. In our effort to explore the 
efficacy and limitation of employing AI for molecular generation while providing comprehensive 
information about PCP site antagonists heretofore missing from existing publicly available small 
molecule databases, we utilized a variety of established in silico techniques currently being used 
to find candidate drug leads. These include ligand- and structure-based methods for activity 
assessment, absorption, distribution, metabolism, and excretion (ADME) prediction, substructure 
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analysis, lead-likeness filters, synthesizability scoring, and similarity metrics. Ultimately, we 
found twelve new potential antagonists that passed all of our filtering steps. All structures were 
not present in any public database and contained unique molecular backbones compared to known 
active antagonists. The results of applying these techniques to AI-generated compounds provide 
insight into some of the advantages afforded by DL for de novo drug design, as well as the 
obstacles. The limitations we identified have the potential to be useful in guiding both our future 
work and, more broadly, the development of generative machine learning models for targeted 
molecule design. 
 
RESULTS AND DISCUSSION.  
In silico Workflow Strategy  
One of our primary objectives was to assess whether our AI-generated compounds would pass 
in silico screens typically utilized during the CADD process to characterize and filter existing 
compounds or compounds created by other in silico or in vitro means. We therefore developed a 
workflow comprised of both ligand- and structure-based techniques commonly used in the drug 
discovery process to screen AI-generated compounds for potential activity at the NMDAR PCP 
site (Figure 2). Our strategy for the creation of de novo candidate PCP site antagonists was to 
search the chemical space (i.e. the VAE latent space) encompassed by the set of experimentally 
verified PCP site antagonists. This necessitated the creation of a library of known actives to define 
a region in latent space from which to sample. Resulting generated compounds were filtered 
according to predicted activity at the binding site, favorable molecular docking score, and desirable 
ADME-Toxicity profiles and synthesizability scores. 
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Figure 2. (A) Workflow schematic: A PCP site library was assembled and used as input to 
DarkChem to train an activity prediction model and collect baseline performance metrics for 
molecular docking simulations. Generated candidate structures were assessed with the ligand-
based activity prediction model and the structure-based molecular docking simulation and then 
further filtered. (B) Detailed representation of the filtering process for AI-generated compounds 
with the number of passing compounds displayed below the filtering step. All molecules that pass 
each step are available upon request. 
 
NMDAR PCP Site Molecular Library 
The lack of publicly available comprehensive data on NMDAR channel blockers necessitated 
the construction of a library of NMDAR PCP site antagonists. We created a library that contains 
1,142 NMDAR PCP site antagonists, with 818 compounds having experimentally derived activity 
at the PCP site and 324 compounds having unknown activity. Some of the dominant chemical 
classes represented include arylcyclohexylamine, dibenzocycloalkenamine, dioxolane, 
benzomorphan, diphenylethylamine, aminoadamantane, aminoalkylcyclohexane, morphinan, and 
guanidine. Classes are primarily defined according to the classifications used by the author(s) in 
BA
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the publication from which the compounds were extracted. If such classifications were not 
provided, applicable class names already present in the library were applied. The library was built 
from an in-depth literature search and web scraping of online databases. A summary of the 
literature-derived library sources is shown in Table 1. Many well-known NMDAR antagonists and 
their analogs are represented, such as PCP, rolicyclidine, ketamine and esketamine, tiletamine, 
lanicemine, methoxetamine, dexoxadrol and etoxadrol, memantine, dextromethorphan and 
dextrorphan, and dizocilpine (MK-801). The chemical properties of the library entries reveal some 
common trends among them including a low molecular weight (µ: 261.03 Da; σ: 63.79 Da) and 
high lipophilicity (µ: 3.75; σ: 1.29) compared to other CNS-active drugs.38 The library also 
contains 2,000 decoy molecules—compounds with physicochemical properties that match actives 
but are topologically different and presumed to be inactive at the site of interest. All compounds 
are represented by their International Union of Pure and Applied Chemistry (IUPAC) name, 
common name where applicable, canonical simplified molecular-input line-entry specification 
(SMILES), and chemical formula. The library was utilized to define a region in the DarkChem 
latent space to search for novel antagonists, build an activity prediction model during ligand-based 
assessment, and determine baseline molecular docking performance metrics.   
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Table 1. Summary of NMDAR PCP site library sources. The full library spreadsheet is 
available in the Supporting Information. 
Chemical Class(es) Source Citation Number of Compounds* 
Dioxolane Aepkers & Wünsch, 2005 39 5 
Aminoacridine Barygin et al., 2009 40 5 
Arylcyclohexylamine, Diphenylethylamine Berger et al., 1998, 2009, 2015 41-43 36 
Arylcyclohexylamine, Dibenzocycloalkenamine, 
Octahydrophenanthrenamine Bigge et al., 1993 
44 47 
Arylcyclohexylamine Chaudieu et al., 1989 45 33 
Arylcyclohexylamine, Arylcyclohexylmorpholine Colestock et al., 2018 46 7 
Arylcyclohexylamine, Benzomorphan, Indenopyridine, 
Benz(f)isoquinoline, Dioxolane Domino & Kamenka, 1988 
47 43 
Arylcyclohexylamine, Guanidine Dravid et al., 2007 48 7 
Phenylpiperidine Ebert et al., 1998 49 18 
Dibenzocycloalkenamine Elhallaoui et al., 2003 50 36 
Dibenzocycloalkenamine Gee et al., 1993, 1994 51,52 24 
Aminoalkylcyclohexane Gilling et al., 2007 53 3 
Quinolone Gordon et al., 2001 54 1 
Tetrahydroisoquinoline, Benzomorphan Gray et al., 1989 55 38 
Hexahydrofluorenamine Hays et al., 1993 56 22 
Guanidine Hu et al., 1997 57 66 
Arylcyclohexylamine Itzhak et al., 1981 58 2 
Diphenylethylamine Kang et al., 2017 59 1 
Arylcyclohexylamine Kozikowski & Pang, 1990 60 12 
Arylcyclohexylamine, Propanolamine Kozlowski et al., 1986 61 9 
Arylcyclohexylamine, Dioxolane, Benzomorphan Largent et al., 1986 62 6 
Arylcyclohexylamine, Isothiocyanate Linders et al., 1993 63 25 
Arylcyclohexylamine, Dioxolane, Benzomorphan, 
Benz(f)isoquinoline, Morphinan Mendelsohn et al., 1984 
64 15 
Dibenzocycloalkenamine Monn et al., 1990 65 20 
Arylmethylguanidine Naumiec et al., 2015 66 17 
Aminoalkylcyclohexylamine, Tetrahydroisoquinoline, 
Imidazoline Nicholson & Balster, 2003 
67 10 
Arylcyclohexylamine, Imidazoline Olmos et al., 1996 68 9 
Aminoalkylcyclohexane, Aminoadamantane Parsons et al., 1995, 1999 69, 70 55 
Arylcyclohexylamine, Adamantine, Aminoadamantane, 
Aminoalkylcyclohexane Rammes et al., 2001 
71 15 
Dibenzocycloalkenamine Rogawski et al., 1991 72 1 
Arylcyclohexylamine, Anisylcyclohexylamine Roth et al., 2013 73 6 
Arylcyclohexylamine Sałat et al., 2015 74 2 
Dioxolane Sax & Wünsch, 2006 Sax et al., 2008 
75, 76 71 
Arylcyclohexylamine Stefek et al., 1990 77 4 
Diphenylethylamine Subramaniam et al., 1996 78 2 
Dibenzocycloalkenamine Thompson et al., 1990 79 73 
Arylcyclohexylamine, Arylcycloheptylamine Thurkauf et al., 1990 80 37 
Aminoadamantane Tikhonova et al., 2004 81 14 
Arylcyclohexylamine, Anisylcyclohexylamine, 
Diphenylethylamine, Benzofuran, Dioxolane 
Wallach, 2014 
Wallach et al., 2016 
Wallach & Brandt, 2018 
36, 82-85 77 
Morphinan Werling et al., 2007 86 2 
Arylcyclohexylamine, Anisylcyclohexylamine Zarantonello et al., 2011 87 12 
Arylcyclohexylamine Zukin & Zukin, 1979 88 31 
*some compounds appear in multiple sources 
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Generation of Potential PCP Site Antagonists 
Our DL-based VAE, DarkChem, was supplied with known actives from the library to seed its 
latent representation of chemical structure, or latent space, defining a bounded volume within 
chemical space from which to sample new potential NMDAR antagonists (see Figure 3 and 
Methods). Ensuing deduplication and SMILES validity verification steps resulted in a set of 
198,826 generated structures. Among this set, all required chemical properties for the activity 
model could be successfully calculated for 5,629 compounds. The remaining downselection steps, 
which are detailed in following sections, further reduced the candidates to twelve optimized 
potential antagonists (Figure 4), none of which were found in the thirty-one chemical databases 
we cross-referenced. These final putative structures were assessed for their proximity to the set of 
known actives to determine whether generated structures were unique and/or novel, as opposed to 
simple perturbations of the input. The distance between each putative structure and active in the 
128-dimension latent space was computed by L1 norm, as it behaves favorably in high dimensions 
compared to the L2 norm,89 and the closest active was selected for each generated structure (Table 
S5). Example final structures are shown with their closest therapeutic active in latent space in 
Figure 3. The primary drawback to the in silico generation of novel molecules is the unavailability 
of chemical standards for an in vitro assessment of their lead-likeness. When (and if) these de novo 
compounds are synthesized, their ability as PCP site antagonists can be assessed to improve the 
accuracy of the in silico pipeline where needed. 
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Figure 3. (A) DarkChem network schematic: The network involved an encoder (green), a latent 
representation (orange), and a decoder (purple). Additionally, a property predictor (slate) was 
attached to the latent representation. For the encoder, layers included SMILES input, character 
embedding, and a series of convolutional layers. The latent representation was a fully connected 
dense layer. The decoder was comprised of convolutional layers, followed by a linear layer with 
softmax activation to yield outputs. Finally, the property predictor was a single dense layer 
connected to the latent representation with 20% dropout. Reprinted with permission from Colby 
et al., 2019. Copyright 2019 American Chemical Society. (B) Latent space: The first two principal 
components of the 128-dimensional representation are shown, colored by predicted property value 
(top: m/z, bottom: CCS). The representation is a 2D binned statistic of the mean, with grid size 
384 in each principal component dimension. A kernel density estimator is also shown for each 
principal component dimension, emphasizing density of the distribution. In teal is the region of 
latent space encompassed by PCP site antagonists. (C) Close-up of PCP site antagonist region of 
latent space: Points 1-8 represent a selection of known PCP site antagonists, and the therapeutic 
subset of known antagonists is represented as A-F. (D) Molecular structures corresponding to 
points 1-8 and A-F. 
 
Ligand-Based Analysis 
Drug screening is a costly and time-consuming process. Many attempts have been made to 
expedite the process by developing metrics to filter lead-like compounds from large libraries of 
contenders based on the physiocochemical properties of the ligands alone. The most famous of 
these metrics is arguably Lipinski’s Rule of Five (Ro5).90 There are many exceptions to the Ro5, 
however, and numerous other metrics have been developed in an effort to improve upon it. The 
current consensus regarding these rules is that while they are a good starting place for filtering 
candidate compounds, they are far from comprehensive. In addition, the Ro5 and similar rules 
have been demonstrated to be less applicable to CNS active compounds.91 They are, however, 
approachable and easy to implement.  
In our work, once properties were calculated for PCP site library compounds, the Ro5 and 
several other filters were applied to ascertain whether they could effectively distinguish between 
active and inactive/decoy compounds. None of the filters performed meaningfully better on the 
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actives, and in fact many filtered out a higher proportion of actives than inactives and decoys. This 
is likely due in part to the highly tuned nature of the inactives and decoys in the library and lends 
further support to the maxim that such rules should only be applied as an early step when filtering 
very large and chemically diverse compound databases. Thus, we applied a more rigorous ligand-
based analysis technique, detailed below, which resulted in a substantially enhanced ability to 
distinguish between active and inactive library compounds. 
Initially, 130 0-, 1-, and 2-D properties, including atom and bond counts, functional group 
counts, and topological indices, respectively, were calculated for all library compounds for 
property analysis. We omitted 3-D properties because they greatly increase computational 
resources and often do not achieve superior performance to 2-D QSAR methods.92-94 Applying the 
library compounds to the principal component analysis (PCA) space of computed properties 
revealed that the actives tend to cluster tightly while the inactives routinely display much larger 
variance (Figure S1). Calculated chemical properties were applied to supervised machine learning 
activity analysis to build a QSAR model. The number of descriptors used in building the model 
was chosen to balance the “curse of dimensionality”, wherein too many descriptors result in 
decreased model performance, with the loss of relevant information that can occur with too few 
features. This approach also follows the recommendation that for building machine learning 
models for QSAR analysis the number of instances should be at least five times the number of 
features.95 
Although developed fairly recently, support vector machines (SVM) have demonstrated 
significant value as activity prediction models.96-97 The SVM model for PCP site activity 
prediction achieved a ten-fold cross-validated accuracy of 0.95, with a weighted average precision 
of 0.98, recall of 0.97, and f1 of 0.97 on the test set (Figure S2). We built the initial classification 
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models using a training set comprised of samples from only the library actives and inactives, which 
resulted in worse than desired performance due to the scarcity of inactives (N=X). Incorporation 
of decoy compounds (N=Y) to the inactive class resulted in the considerably more accurate and 
robust final model built for activity prediction. Decoys are an integral part of the CADD process, 
used both as controls for assessing docking simulation results and for building QSAR models in 
the absence of sufficient known inactive compounds. While there is a degree of inherent 
uncertainty when using decoys, as presumed inactivity does not necessarily equate to true 
inactivity, the application of an unpaired t-test on the binding outcomes of a docking study of 
library actives, inactives, and decoys demonstrated statistically significant differences between 
actives and inactives and between actives and decoys that did not exist between inactives and 
decoys. This is discussed in further detail in the next section. These results provided confidence in 
incorporating the decoys to the inactive class for activity model training. To avoid overfitting, a 
frequent pitfall of QSAR models,98 we assessed the robustness of our model using both ten-fold 
cross-validation and a randomly generated test set comprised of data not seen in training. The 
model’s cross-validated accuracy of 0.95 and AUPR of 0.95 demonstrate its usefulness as an 
assessment tool for PCP site activity. The code for the SVM is available as a Python notebook in 
the Supporting Information. The SVM model predicted 628 of the 5,628 generated compounds 
with successfully calculated properties as active. 
Structure-Based Analysis 
There are two 3D crystallographic NMDAR structures with a PCP site-bound ligand available: 
Protein Data Bank (PDB) codes 5UOW99 and 5UN1.30 The structures were compared by running 
trial docking simulations following the same receptor preparation method, after which the higher 
resolution structure 5UN1 (3.6 Å) was chosen for the library and de novo compound docking 
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studies. AutoDock Vina outputs the top binding poses and scores for each ligand. A ligand’s score 
represents the estimated free energy of binding, where a more negative score corresponds to a 
higher likelihood of binding. Vina’s energy of binding estimates contain widely reported 
inconsistencies and should not be assumed to represent correct values for the purposes of ranking, 
but they have been demonstrated to be accurate in predicting binding poses and distinguishing 
between active and inactive compounds in the aggregate.100 A common method for docking 
assessment is to determine how well docking scores correlate to experimental binding affinities 
for a given library of compounds. However, this approach is problematic due to the fact that 
experimental binding affinities present in ligand libraries are extracted from multiple sources with 
varying experimental parameters, including the location of the receptor in the body. We therefore 
decided on an alternative approach to docking wherein the ability to distinguish between verified 
active, verified inactive, and decoy compounds using docking scores was assessed. We found that 
the docking scores for the library compounds display a statistically significant difference between 
the active and inactive compounds as well as between the active and decoy compounds (two-tailed 
p < 0.0001 for both), but not between the decoys and inactives (two-tailed p = 0.3, Table S2). This 
result lends support to the use of docking studies for assessing potential activity of novel PCP site 
antagonists and, more generally, provides confidence in this approach to docking for activity 
analysis. 
A noteworthy finding was that the mean docking score for the DarkChem-generated compounds 
was less negative than for any of the library compound classes. While individual docking scores 
were not found to correlate with activity, the mean scores for each library class were 
distinguishable. This finding could reflect a shortcoming of the present generative AI approach 
and indicate a need to incorporate receptor structural data into the molecular generation process. 
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A comparative assessment of generative models with and without the inclusion of structural 
information would be a valuable area for future work, and we are currently expanding DarkChem 
to include hundreds of chemical properties along with a valid-structure discriminator in order to 
improve candidate generation.  
A common bottleneck in DL models is the requirement of large quantities of high-quality data. 
In drug discovery DL applications as in others, more information is typically correlated with better 
model performance.101 Therefore, for this work we selected the 473 molecules with docking scores 
in the actives scoring range to proceed to the next stages of filtering. 
Further Assessment of Generated Compounds and Top Final Leads 
None of the generated structures were found to exist in the thirty-three compound databases that 
were cross-referenced for duplicates. ADME-Toxicity, predicted off-site activity, synthesizability, 
and stability filters were applied to the remaining compounds next (details in Methods). In line 
with the goal of assisting in the identification of unique scaffolds of molecules with PCP site 
activity to aid in the search for potentially therapeutic compounds, the filter tolerances were set to 
be consistent with the properties of known therapeutic actives from the library. This screening 
process reduced the number of compounds to twelve finalists (Figure 4). As the failure to 
accurately account for breakdown products has been implicated as the cause of many lead failures 
during the drug discovery process,102 we predicted metabolites for each of the twelve candidates 
(see metabolites xlsx file in Supporting Information). 
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Figure 4. (A) Close-up of the first two PCA dimensions from DarkChem’s latent space 
encompassed by the twelve generated finalist molecules, labeled as a-l. (B) The twelve generated 
finalist structures with their letter designation corresponding to that in A. 
 
Similarity assessment of the final structures to the library actives training set revealed that the 
generated compounds were unique and not merely simple perturbations of the input. Of the twenty 
most common unique substructures found in at least 50% of the library actives, each substructure 
is represented in no more than 0.25% of the set of generated compounds. In addition, each of the 
final twelve compounds contain only between one and eight of the twenty common substructures 
(Table S3, Table S4). Finalist compounds also display a high degree of uniqueness when compared 
to the training set using L1 distance and Tanimoto score metrics (Figure 5). The most similar active 
training set compounds by L1 distance in 128-dimensional space and by Tanimoto score are 
reported for each finalist molecule in Table S5. The ability of generated compounds to pass 
multiple stages of standard CADD filtering processes demonstrates the promise of this technique 
in application to challenging targets. However, the lack of in vitro and in vivo experimental data 
for verification and benchmarks for quality assessment pose immediate challenges to a robust 
assessment of this and other DL-assisted generative models. Furthermore, while the finalist 
molecules all have favorable synthesizability scores, true synthesizability and stability are difficult 
to assess and many of the generated compounds are somewhat peculiar looking. To improve DL-
assisted de novo design methods, representing compounds for DL models as molecular graph 
convolutions instead of SMILES strings has shown promise as a superior mode of structural 
representation.103 We plan to transition future versions of DarkChem to graph convolution 
molecular representations to improve the ability to generate increasingly realistic, stable 
compounds. 
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Figure 5. Finalist generated structures display a high degree of uniqueness compared to training 
set molecules. Representative finalist compounds, the three leftmost molecules, are juxtaposed 
with the most similar training set therapeutic by L1 distance and the most similar training set active 
by Tanimoto score. 
 
Current State of AI for De Novo Molecular Design 
AI is demonstrating promise as a tool in the drug design and discovery process. However, the 
field is in its infancy and is regularly described with either over-inflated hype about what it can 
deliver or harsh derision and dismissal. As such, many in the field are calling for a more measured 
approach coupled with the development of suitable guidelines for measuring performance of AI 
models to better understand current limitations and possibilities.104 While sensationalist headlines 
would have one believe that we are nearing the point in which AI can effectively generate novel 
drugs with desirable in vivo properties for a target of interest, the reality is that current generative 
models have a considerable way to go before that claim can reasonably be made. In fact, it may 
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not be possible for a single AI to autonomously design drugs; it could be that the best outcome 
will arise from a suite of AI models used in concert at various stages of the drug design and 
optimization process. Furthermore, the ideal model(s) might be dependent on the individual target 
rather than being universal.105 There are many suggestions regarding specific intermediate goals 
that the AI drug design community should strive to achieve in an effort to establish standards by 
which generative models can be judged. One such suggested near-term goal is for generative 
models to demonstrate the effective shrinking of the vast search space used by traditional virtual 
and high-throughput screening methods.106 However, the means by which to demonstrate success 
at such a task is up for debate. A large obstacle facing the AI drug design community is that there 
is no current “best practice” for assessing performance. It is widely agreed that at a minimum, the 
similarity of generated molecules to training molecules should be assessed. Other suggestions 
include comparing output to that produced by other drug design tools and bioisosteric replacement 
methods, assessment of activity at off-targets, and sensitivity analysis of how data quality and 
quantity affect output. To begin to fill this gap, some nascent benchmarking sets have recently 
been introduced.8, 107 While the authors highlight the inherent difficult in creating objective quality 
metrics and note that many of the benchmarks are too easily solved by most DL-based de novo 
design models, the benchmarks offer a promising initial step in the development of robust quality 
assessment techniques.  
 
CONCLUSION. In summary, we produced a library of NMDAR PCP site antagonists including 
known actives, known inactives, and decoys. We demonstrated the application of this library to 
the AI-assisted generation of structurally unique putative active compounds targeting a more 
complex site than previously seen that were then downselected using standard CADD techniques. 
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We identified current limitations of generative models in de novo design including the absence of 
receptor structural information during the training process and the lack of existing baselines for 
comparison. While the ability of AI-generated compounds to pass ligand- and structure-based 
filters for a complex target is promising, we advise that rigorous benchmarks are needed for more 
robust assessment of this technology. 
 
METHODS.  
NMDAR Antagonist Library 
The NMDAR PCP site antagonist library was built by extracting from a comprehensive literature 
search for experimental Ki and IC50 values of ligands used in PCP site binding assays.33, 36, 39-71, 73-
88, 108-116 Ligands with Ki values less than 100 µM were placed in the ‘Actives’ section of the 
library, and those 100 µM or greater were placed in the ‘Inactives’ section. The library contains 
728 active and 87 inactive literature-verified compounds, and 297 PCP analogs and near-analogs 
without binding data scraped from the website isomerdesign.com. The html code from the page 
was parsed using the Python library BeautifulSoup117 by visiting every compound stored under the 
tag ‘arylcycloalkylamine’ and extracting the molecular information. A set of thirty-nine actives 
from a single study83 (‘validation1’ in Figure S1) with a wide range of PCP site activities were 
used to seed the generation of decoy molecules using the Database of Useful Decoys: Enhanced 
(DUD-E) database,118 which were added to the library. All library compounds are represented by 
their canonical SMILES. Canonicalization was performed using OpenBabel (version 2.4.1, 
2019, http://openbabel.org).119 The complete library can be found in Supporting Information. 
Ligand- and Structure-Based Analysis 
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Both 1- and 2-D physiocochemical properties were calculated for each of library compounds 
using ChemAxon’s cxcalc (version 5.2.0, http://www.chemaxon.com). The properties were 
normalized and applied to the chemical property PCA space using the Python library scikit-
learn,120 in which PCA space was defined following the method outlined in the Colby et al. 
DarkChem publication.121 
The library compounds were split into training and test sets (75%/25%) using stratified random 
sampling with ten-fold cross-validation to account for the imbalance between classes. An SVM 
binary classification model for predicting binding affinity was built and trained on the training set 
with scikit-learn, with performance assessed using recall, precision, f1 score, and area under the 
precision-recall curve (AUPR). The properties used in model building are enumerated in Table S1. 
Structure-based analysis was performed using a 3D crystallographic structure of the NMDAR 
(PDB code 5UN1) downloaded from www.rcsb.com.30 The receptor was prepared with Chimera122 
by removing the bound ligand MK-801 after creating a centroid to extract the center coordinates 
of the bound ligand. Next, the Chimera structure editing “dock prep” feature was run with the 
option to consider H-bonds, the AMBER ff14sb option to include charges for standard residues, 
and the AM1-BCC option to include charges for non-standard residues. The resulting NMDAR 
structure was saved for docking in PDB format after removing all hydrogens. Using this structure, 
the active, inactive, and decoy compounds from the library were run through an AutoDock Vina123 
docking simulation using PyRX124, where the previously extracted centroid coordinates were used 
to define the search space in the protein. The top eight pose scores, or the maximum number found 
if below eight, were collected for each compound. 
De Novo Design of Potential Channel Blockers 
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Putative structures were generated using DarkChem, a SMILES-based VAE implementation 
with coupled property predictor, with model parameters matching those of Colby et al.26 The 
model was initialized with pretrained weights from a transfer learning configuration including 
~55M mass-labeled compounds from PubChem;100 ~700K mass- and computed collision cross 
section (CCS)- labeled compounds from the union of the Universal Natural Product Database,125 
Human Metabolome Database,126 and Distributed Structure-searchable Toxicity127 datasets; and 
~500 mass- and experimental CCS- labeled compounds curated from the literature. This pretrained 
model was used to encode the set of 728 known NMDAR actives into a 128-dimension latent 
vector representation of molecular structure.  The mean and variance of the actives was calculated 
for each dimension and used to define a 128-dimension random normal distribution from which 
100K latent vectors were sampled. Each latent vector was decoded to the k most probable 
structures using beamsearch (k=100), resulting in 10M putative structures. These were initially 
downselected by SMILES canonicalization and duplicate removal, checking for SMILES validity 
using rdkit (rdkit.org), and ensuring sampled latent vectors fell within the convex hull defined by 
the 728 known actives, reducing the putative set to 198,826. The convex hull was constructed from 
the first 8 principal components of the latent representation using the Quickhull128 algorithm from 
the spatial module of SciPy.129 
Downselection of Generated Compounds 
The remaining structures were assessed for potential PCP site activity by being tested against 
the classification model. Passing compounds were then run through the same docking simulation 
as the library compounds. The compounds with docking scores in the range of known actives were 
assessed for synthesizability and filtered for desirable ADME properties using SwissADME,130 for 
which the known therapeutic PCP site actives memantine, ketamine, dextromethorphan, and 
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amantadine were used as a basis for comparison. A synthetic accessibility score of six or higher 
(on a scale of one to ten) was considered undesirable. Drug- and lead-likeness violations were only 
accepted if any of the known PCP site therapeutics contained the same violation. Predicted activity 
at any of the set of receptors checked by SwissADME was also only accepted if any known 
therapeutics demonstrated the same prediction. Remaining compounds were then filtered for 
desirable gastrointestinal absorption, blood-brain barrier permeability, and solubility. The passing 
molecules were further compared against the known therapeutics and filtered to those containing 
at least one hydrogen bond acceptor, no more than six heavy aromatic atoms, at least one nitrogen 
atom, and a consensus logP between two and four. A link to the Jupyter notebook containing the 
filtering script is included in Supporting Information. The twelve finalist compounds were cross-
referenced against a chemical library comprised of a collection of thirty-one chemical databases 
and websites to determine their novelty.125-126, 131-159 Predicted metabolites for each of the twelve 
finalist compounds were generated using BioTransformer135 and are reported in Supporting 
Information. 
Similarity Assessment of AI-Generated Compounds to Known Actives 
Substructure assessment was conducted utilizing graph theory (i.e. subgraph isomorphism) 
where the molecular graph was defined by a set of nodes (i.e. atoms) and a set of connecting edges 
(i.e. bonds). Substructures ranging in size from one atom of a molecule to the entire molecule were 
found in two stages. In the first stage, only the paths consisting of a straight chain of nodes where 
each node is connected to every other in the molecule were found. Breadth-first search was used 
to find every possible path in the molecule by starting with an arbitrary atom in a molecular graph 
and exploring by degree, starting from all first-degree neighbor nodes and then moving to one-
degree deeper nodes until all connecting nodes were visited. In the second stage, paths containing 
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branches were searched using depth-first search by exploring each node branch to the deepest level 
from the starting node until no more connections were found. As a result, branches were mapped 
to the chain paths at possible positions. Obtained substructures were stored as canonical SMILES. 
The distance between each finalist structure and active in the 128-dimension space was 
computed by L1 norm. The Tanimoto similarity between each of the twelve final structures and 
every library active was computed using RDKit. The similarity scores were evaluated to locate the 
nearest active by L1 norm and Tanimoto similarity to each finalist molecule.  
 
ASSOCIATED CONTENT. 
Supporting Information. NMDAR PCP site library, enumerated compounds at each stage of 
screening, additional figures and tables illustrating activity model assessment, PCA, docking 
numerics, and similarity assessment, ADME-based filtering script, QSAR SVM script, and 
predicted metabolites.  
The following files are available free of charge. 
NMDAR PCP Site Library (XLSX) 
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